From the list of identified DEPs as potential drug targets for sepsis (listed in “All FDA-approved therapeutics and pre(clinical) trial therapeutics targeting the DEPs” Supplementary Table 3), nine DEPs (CDC42, TAOK1, FPR1, VTN, H2AC21, PPP2CA, CACNA1G, TRPV2, ATP2B1) were directly implicated in known neutrophil processes related to sepsis. Here, TRPV2 is linked to Sepsis.